Zi‐Ning Lei

2.9k total citations · 2 hit papers
72 papers, 2.2k citations indexed

About

Zi‐Ning Lei is a scholar working on Oncology, Molecular Biology and Infectious Diseases. According to data from OpenAlex, Zi‐Ning Lei has authored 72 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Oncology, 44 papers in Molecular Biology and 19 papers in Infectious Diseases. Recurrent topics in Zi‐Ning Lei's work include Drug Transport and Resistance Mechanisms (50 papers), Cancer therapeutics and mechanisms (29 papers) and HIV/AIDS drug development and treatment (18 papers). Zi‐Ning Lei is often cited by papers focused on Drug Transport and Resistance Mechanisms (50 papers), Cancer therapeutics and mechanisms (29 papers) and HIV/AIDS drug development and treatment (18 papers). Zi‐Ning Lei collaborates with scholars based in United States, China and Pakistan. Zi‐Ning Lei's co-authors include Zhe‐Sheng Chen, Qiu‐Xu Teng, Jing‐Quan Wang, Chao‐Yun Cai, Yuqi Yang, Dong‐Hua Yang, Leli Zeng, Pranav Gupta, Zhuo‐Xun Wu and Yihang Pan and has published in prestigious journals such as SHILAP Revista de lepidopterología, Cancer Research and International Journal of Molecular Sciences.

In The Last Decade

Zi‐Ning Lei

71 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Understanding and targeting resistance mechanisms in cancer

2023 177 citations Zi‐Ning Lei, Tian Qin et al. SHILAP Revista de lepidopterología profile →
Signaling pathways and therapeutic interventions in gastric cancer

2022 167 citations Zi‐Ning Lei, Qiu‐Xu Teng et al. Signal Transduction and Targeted Therapy profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Zi‐Ning Lei United States	29	1.2k	1.2k	322	306	200	72	2.2k
Kristen M. Pluchino United States	10	1.1k 0.9×	1.0k 0.8×	207 0.6×	293 1.0×	163 0.8×	14	2.0k
Qiu‐Xu Teng United States	25	964 0.8×	932 0.8×	206 0.6×	261 0.9×	164 0.8×	50	1.6k
Chao‐Yun Cai China	24	849 0.7×	862 0.7×	210 0.7×	179 0.6×	150 0.8×	40	1.6k
Rishil J. Kathawala United States	22	1.2k 0.9×	904 0.7×	236 0.7×	183 0.6×	171 0.9×	31	1.7k
Qingbin Cui China	22	679 0.6×	1.0k 0.8×	135 0.4×	285 0.9×	109 0.5×	49	1.8k
Yi‐Jun Wang United States	29	1.6k 1.3×	982 0.8×	209 0.6×	215 0.7×	128 0.6×	75	2.5k
Donglai Shen China	19	1.7k 1.4×	1.6k 1.3×	254 0.8×	260 0.8×	280 1.4×	38	2.6k
Zhirong Zhan United States	21	1.8k 1.5×	1.6k 1.3×	261 0.8×	317 1.0×	438 2.2×	33	2.8k
Yong‐ju Liang China	27	1.4k 1.1×	1.1k 0.9×	220 0.7×	171 0.6×	133 0.7×	43	2.2k
Jean‐Pierre Gillet United States	16	876 0.7×	1.0k 0.8×	136 0.4×	231 0.8×	110 0.6×	29	1.7k

Countries citing papers authored by Zi‐Ning Lei

Since Specialization

Citations

This map shows the geographic impact of Zi‐Ning Lei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zi‐Ning Lei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zi‐Ning Lei more than expected).

Fields of papers citing papers by Zi‐Ning Lei

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zi‐Ning Lei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zi‐Ning Lei. The network helps show where Zi‐Ning Lei may publish in the future.

Co-authorship network of co-authors of Zi‐Ning Lei

This figure shows the co-authorship network connecting the top 25 collaborators of Zi‐Ning Lei. A scholar is included among the top collaborators of Zi‐Ning Lei based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zi‐Ning Lei. Zi‐Ning Lei is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhang, Meng, Qiu‐Xu Teng, Zi‐Ning Lei, et al.. (2024). Mobocertinib antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells: In vitro and in vivo studies. Cancer Letters. 607. 217309–217309. 6 indexed citations

Wang, Siqi, Yuchen Jiang, Zi‐Ning Lei, et al.. (2023). Targeting GSTP1 as Therapeutic Strategy against Lung Adenocarcinoma Stemness and Resistance to Tyrosine Kinase Inhibitors. Advanced Science. 10(7). e2205262–e2205262. 26 indexed citations

Lei, Zi‐Ning, Tian Qin, Qiu‐Xu Teng, et al.. (2023). Understanding and targeting resistance mechanisms in cancer. SHILAP Revista de lepidopterología. 4(3). e265–e265. 177 indexed citations breakdown →

Wang, Saiqi, Qiu‐Xu Teng, Shuai Wang, et al.. (2022). Preclinical studies of the triazolo[1,5-a]pyrimidine derivative WS-716 as a highly potent, specific and orally active P-glycoprotein (P-gp) inhibitor. Acta Pharmaceutica Sinica B. 12(8). 3263–3280. 24 indexed citations

Lei, Zi‐Ning, Qiu‐Xu Teng, Tian Qin, et al.. (2022). Signaling pathways and therapeutic interventions in gastric cancer. Signal Transduction and Targeted Therapy. 7(1). 358–358. 167 indexed citations breakdown →

Wang, Jing‐Quan, Zhuo‐Xun Wu, Yuqi Yang, et al.. (2021). ATP‐binding cassette (ABC) transporters in cancer: A review of recent updates. Journal of Evidence-Based Medicine. 14(3). 232–256. 105 indexed citations

Lei, Zi‐Ning, Qiu‐Xu Teng, Zhuo‐Xun Wu, et al.. (2021). Overcoming multidrug resistance by knockout of ABCB1 gene using CRISPR/Cas9 system in SW620/Ad300 colorectal cancer cells. SHILAP Revista de lepidopterología. 2(4). 765–777. 36 indexed citations

Wang, Jing‐Quan, Qiu‐Xu Teng, Zi‐Ning Lei, et al.. (2020). Venetoclax, a BCL-2 Inhibitor, Enhances the Efficacy of Chemotherapeutic Agents in Wild-Type ABCG2-Overexpression-Mediated MDR Cancer Cells. Cancers. 12(2). 466–466. 48 indexed citations

Wu, Zhuo‐Xun, Yuqi Yang, Guangsuo Wang, et al.. (2020). Dual TTK/CLK2 inhibitor, CC‐671, selectively antagonizes ABCG2‐mediated multidrug resistance in lung cancer cells. Cancer Science. 111(8). 2872–2882. 28 indexed citations

10.

Wang, Jingqiu, Dong‐Hua Yang, Yuqi Yang, et al.. (2020). Overexpression of ABCB1 Transporter Confers Resistance to mTOR Inhibitor WYE-354 in Cancer Cells. International Journal of Molecular Sciences. 21(4). 1387–1387. 33 indexed citations

11.

Gupta, Pranav, Zi‐Ning Lei, Sandra E. Reznik, et al.. (2020). BMS-599626, a Highly Selective Pan-HER Kinase Inhibitor, Antagonizes ABCG2-Mediated Drug Resistance. Cancers. 12(9). 2502–2502. 13 indexed citations

12.

Wang, Shuai, Saiqi Wang, Qiu‐Xu Teng, et al.. (2020). Structure-Based Design, Synthesis, and Biological Evaluation of New Triazolo[1,5- a ]Pyrimidine Derivatives as Highly Potent and Orally Active ABCB1 Modulators. Journal of Medicinal Chemistry. 63(24). 15979–15996. 41 indexed citations

13.

Arnst, Kinsie E., Yuxi Wang, Zi‐Ning Lei, et al.. (2019). Colchicine Binding Site Agent DJ95 Overcomes Drug Resistance and Exhibits Antitumor Efficacy. Molecular Pharmacology. 96(1). 73–89. 26 indexed citations

14.

Wu, Zhuo‐Xun, Qiu‐Xu Teng, Chao‐Yun Cai, et al.. (2019). Tepotinib reverses ABCB1-mediated multidrug resistance in cancer cells. Biochemical Pharmacology. 166. 120–127. 57 indexed citations

15.

Liao, Dan, Wei Zhang, Pranav Gupta, et al.. (2019). Tetrandrine Interaction with ABCB1 Reverses Multidrug Resistance in Cancer Cells Through Competition with Anti-Cancer Drugs Followed by Downregulation of ABCB1 Expression. Molecules. 24(23). 4383–4383. 55 indexed citations

16.

Ji, Ning, Yuqi Yang, Chao‐Yun Cai, et al.. (2018). Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells. Cancer Letters. 440-441. 82–93. 91 indexed citations

17.

Wang, Qinghui, Kinsie E. Arnst, Yi Xue, et al.. (2018). Synthesis and biological evaluation of indole-based UC-112 analogs as potent and selective survivin inhibitors. European Journal of Medicinal Chemistry. 149. 211–224. 19 indexed citations

18.

Fan, Yingfang, Wei Zhang, Leli Zeng, et al.. (2018). Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters. Cancer Letters. 421. 186–198. 96 indexed citations

19.

Gupta, Pranav, Zi‐Ning Lei, Dan Liao, et al.. (2018). Immuno-oncology agent IPI-549 is a modulator of P-glycoprotein (P-gp, MDR1, ABCB1)-mediated multidrug resistance (MDR) in cancer: In vitro and in vivo. Cancer Letters. 442. 91–103. 49 indexed citations

20.

Zhang, Yunkai, Yi‐Jun Wang, Zi‐Ning Lei, et al.. (2018). Regorafenib antagonizes BCRP-mediated multidrug resistance in colon cancer. Cancer Letters. 442. 104–112. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact